Literature DB >> 32207565

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.

Douglas J Harrison1, Jonathan D Gill1, Michael E Roth1, Wendong Zhang1, Beverly Teicher2, Stephen Erickson3, Greg Gatto3, Raushan T Kurmasheva4, Peter J Houghton4, Malcolm A Smith2, Edward Anders Kolb5, Richard Gorlick1.   

Abstract

BACKGROUND: Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1-3. PROCEDURES: The in vivo anticancer effects of regorafenib were assessed in a panel of six osteosarcoma models, three rhabdomyosarcoma models, and one Ewing sarcoma model.
RESULTS: Regorafenib induced modest inhibition of tumor growth in the models evaluated.
CONCLUSION: The overall pattern of response to regorafenib appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models, limited to the period of agent administration, being the primary treatment effect.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; multitarget kinase inhibitor; osteosarcoma; patient derived xenograft; pediatric preclinical testing consortium; rhabdomyosarcoma

Mesh:

Substances:

Year:  2020        PMID: 32207565      PMCID: PMC8670258          DOI: 10.1002/pbc.28222

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  21 in total

1.  Pazopanib for second recurrence of osteosarcoma in pediatric patients.

Authors:  Katsutsugu Umeda; Itaru Kato; Satoshi Saida; Takeshi Okamoto; Souchi Adachi
Journal:  Pediatr Int       Date:  2017-07-06       Impact factor: 1.524

2.  Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Authors:  Florence Duffaud; Olivier Mir; Pascaline Boudou-Rouquette; Sophie Piperno-Neumann; Nicolas Penel; Emanuelle Bompas; Corinne Delcambre; Elsa Kalbacher; Antoine Italiano; Olivier Collard; Christine Chevreau; Esma Saada; Nicolas Isambert; Jessy Delaye; Camille Schiffler; Corinne Bouvier; Vincent Vidal; Sylvie Chabaud; Jean-Yves Blay
Journal:  Lancet Oncol       Date:  2018-11-23       Impact factor: 41.316

3.  Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Authors:  Lara E Davis; Vanessa Bolejack; Christopher W Ryan; Kristen N Ganjoo; Elizabeth T Loggers; Sant Chawla; Mark Agulnik; Michael B Livingston; Damon Reed; Vicky Keedy; Daniel Rushing; Scott Okuno; Denise K Reinke; Richard F Riedel; Steven Attia; Leo Mascarenhas; Robert G Maki
Journal:  J Clin Oncol       Date:  2019-04-23       Impact factor: 44.544

4.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors:  Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

5.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Authors:  G Grignani; E Palmerini; P Dileo; S D Asaftei; L D'Ambrosio; Y Pignochino; M Mercuri; P Picci; F Fagioli; P G Casali; S Ferrari; M Aglietta
Journal:  Ann Oncol       Date:  2011-04-28       Impact factor: 32.976

6.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

7.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

8.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Brenda J Weigel; Elizabeth Lyden; James R Anderson; William H Meyer; David M Parham; David A Rodeberg; Jeff M Michalski; Douglas S Hawkins; Carola A S Arndt
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

10.  Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.

Authors:  Jo Lynne Rokita; Komal S Rathi; Maria F Cardenas; Kristen A Upton; Joy Jayaseelan; Katherine L Cross; Jacob Pfeil; Laura E Egolf; Gregory P Way; Alvin Farrel; Nathan M Kendsersky; Khushbu Patel; Krutika S Gaonkar; Apexa Modi; Esther R Berko; Gonzalo Lopez; Zalman Vaksman; Chelsea Mayoh; Jonas Nance; Kristyn McCoy; Michelle Haber; Kathryn Evans; Hannah McCalmont; Katerina Bendak; Julia W Böhm; Glenn M Marshall; Vanessa Tyrrell; Karthik Kalletla; Frank K Braun; Lin Qi; Yunchen Du; Huiyuan Zhang; Holly B Lindsay; Sibo Zhao; Jack Shu; Patricia Baxter; Christopher Morton; Dias Kurmashev; Siyuan Zheng; Yidong Chen; Jay Bowen; Anthony C Bryan; Kristen M Leraas; Sara E Coppens; HarshaVardhan Doddapaneni; Zeineen Momin; Wendong Zhang; Gregory I Sacks; Lori S Hart; Kateryna Krytska; Yael P Mosse; Gregory J Gatto; Yolanda Sanchez; Casey S Greene; Sharon J Diskin; Olena Morozova Vaske; David Haussler; Julie M Gastier-Foster; E Anders Kolb; Richard Gorlick; Xiao-Nan Li; C Patrick Reynolds; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard B Lock; Pichai Raman; David A Wheeler; John M Maris
Journal:  Cell Rep       Date:  2019-11-05       Impact factor: 9.423

View more
  2 in total

Review 1.  Regorafenib for the Treatment of Sarcoma.

Authors:  Jean-Yves Blay; Florence Duffaud; Suzanne George; Robert G Maki; Nicolas Penel
Journal:  Curr Treat Options Oncol       Date:  2022-09-30

2.  Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib.

Authors:  Takashi Higuchi; Kentaro Igarashi; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Michael Bouvet; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.